Loading...
•
Sep 30, 2021
Bio-Techne Q1 2022 Earnings Report
Bio-Techne's Q1 2022 earnings were released, showcasing strong organic growth and increased profitability.
Key Takeaways
Bio-Techne reported a strong start to fiscal year 2022, with a 26% increase in net sales to $257.7 million and organic revenue growth of 21%. GAAP EPS was $1.69, up from $0.83 in the same quarter last year, and adjusted EPS increased to $1.83 from $1.43. The company experienced broad strength across its portfolio, particularly in the Protein Sciences segment, and made significant progress in its Cell and Gene Therapy initiatives.
Organic revenue increased by 21% to $257.7 million.
GAAP EPS was $1.69, compared to $0.83 in the prior year.
Adjusted EPS was $1.83, up from $1.43 in the prior year.
Protein Sciences segment achieved 26% organic growth.
Revenue by Segment
Forward Guidance
No forward guidance provided in this report.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...